30 Jun 2026Platypus Asset ManagementHUBHeldPlatypus Asset Management continues to hold Hub24 after the holding detracted, weighed down first by concerns that platform inflows may be slowing given heightened Federal Budget uncertainty, and then by ASIC's announcement of a further review into wealth platforms and their superannuation trustees aimed at increasing oversight over platform products.
30 Nov 2025Platypus Asset ManagementCSLHeldPlatypus Asset Management notes CSL's history from its 1994 ASX privatisation through more than two decades of successful global plasma industry expansion via disciplined acquisitions such as ZLB Bioplasma and Aventis Behring, contrasted against a difficult past five years of operational missteps that have damaged its long track record. Platypus highlights a delayed rollout of the Rika plasmapheresis platform, the failed AEGIS-II trial, underestimation of competing FcRn inhibitor therapies, and an underperforming, oversized Vifor Pharma acquisition compounded by COVID-19 impacts on plasma collection costs and Vifor's core population. Platypus points to deteriorating earnings quality, repeated guidance downgrades since a 2023 profit warning, the August 2025 withdrawal of promised CSL Behring gross profit margin recovery, and a shelved in-specie Seqirus distribution as having eroded management credibility and driven a valuation derating to levels last seen during the global financial crisis. Platypus believes investors need clear evidence CSL is returning to its historical standard of execution and discipline before the stock can re-rate.
Platypus Asset Management is a Sydney-based boutique Australian equities fund manager specializing in growth-oriented investing, seeking companies with above-average earnings growth potential trading at reasonable valuations. The firm applies active, research-driven stock selection across the Australian market, aiming to identify structural growth winners ahead of broader market recognition. Platypus operates under a boutique structure with institutional-grade distribution support, serving adviser, wholesale and institutional clients seeking growth-style Australian equity exposure as a complement to value or index-based strategies. The firm's investment process combines top-down thematic views with bottom-up company analysis to build a concentrated, growth-tilted portfolio.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.
30 Jun 2026Platypus Asset ManagementHUBHeldPlatypus Asset Management continues to hold Hub24 after the holding detracted, weighed down first by concerns that platform inflows may be slowing given heightened Federal Budget uncertainty, and then by ASIC's announcement of a further review into wealth platforms and their superannuation trustees aimed at increasing oversight over platform products.
30 Nov 2025Platypus Asset ManagementCSLHeldPlatypus Asset Management notes CSL's history from its 1994 ASX privatisation through more than two decades of successful global plasma industry expansion via disciplined acquisitions such as ZLB Bioplasma and Aventis Behring, contrasted against a difficult past five years of operational missteps that have damaged its long track record. Platypus highlights a delayed rollout of the Rika plasmapheresis platform, the failed AEGIS-II trial, underestimation of competing FcRn inhibitor therapies, and an underperforming, oversized Vifor Pharma acquisition compounded by COVID-19 impacts on plasma collection costs and Vifor's core population. Platypus points to deteriorating earnings quality, repeated guidance downgrades since a 2023 profit warning, the August 2025 withdrawal of promised CSL Behring gross profit margin recovery, and a shelved in-specie Seqirus distribution as having eroded management credibility and driven a valuation derating to levels last seen during the global financial crisis. Platypus believes investors need clear evidence CSL is returning to its historical standard of execution and discipline before the stock can re-rate.
Thesis Tracker